Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given an average recommendation of “Buy” by the sixteen ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.5833.

DNLI has been the subject of a number of recent analyst reports. Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a report on Monday, November 17th. BTIG Research reissued a “buy” rating and set a $32.00 price objective on shares of Denali Therapeutics in a research note on Friday, December 5th. JPMorgan Chase & Co. upped their price objective on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Finally, Wedbush lowered their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNLI. Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics during the 2nd quarter valued at approximately $26,000. Johnson Financial Group Inc. acquired a new stake in Denali Therapeutics in the third quarter valued at $29,000. State of Wyoming acquired a new stake in Denali Therapeutics in the second quarter valued at $29,000. Quarry LP bought a new position in Denali Therapeutics during the 3rd quarter valued at $64,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Denali Therapeutics by 15.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $17.20 on Friday. The business has a 50 day moving average price of $17.30 and a 200 day moving average price of $15.49. The company has a market capitalization of $2.52 billion, a P/E ratio of -5.91 and a beta of 1.11. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $24.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same quarter last year, the firm posted ($0.63) EPS. Denali Therapeutics’s revenue was up .0% on a year-over-year basis. Sell-side analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.